Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma

The ganglioside GD2 is an important target in childhood cancer. Nevertheless, the only therapy targeting GD2 that is approved to date is the monoclonal antibody dinutuximab, which is used in the therapy of neuroblastoma. The relevance of GD2 as a target in other tumor entities remains to be elucidat...

Full description

Bibliographic Details
Main Authors: Arthur Wingerter, Khalifa El El Malki, Roger Sandhoff, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Lehmann, Nadine Vewinger, Katrin B. M. Frauenknecht, Clemens J. Sommer, Frank Traub, Thomas Kindler, Alexandra Russo, Henrike Otto, André Lollert, Gundula Staatz, Lea Roth, Claudia Paret, Jörg Faber
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
ganglioside
GD2
dinutuximab
eliglustat
miglustat
H3K27M-mutant diffuse midline glioma
Online Access:https://www.mdpi.com/2072-6694/13/3/520

Internet

https://www.mdpi.com/2072-6694/13/3/520

Similar Items